Virginia Contreras
Psychiatry · Bronx, NYNPI 1477614295
Payments from drug & device makers
Across 353 payments — averaging $23.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Alkermes, Inc.$966
- Lundbeck LLC$920
- Neurocrine Biosciences, Inc.$900
- Johnson & Johnson$747
- E.r. Squibb & Sons, L.L.C.$622
- plus $2K from 9 others
What the payments were for
- Food & beverage$8,22997%
- Education$2253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 89 | $2,336 |
| Alkermes, Inc. | 50 | $966 |
| Lundbeck LLC | 51 | $920 |
| Neurocrine Biosciences, Inc. | 29 | $900 |
| Johnson & Johnson | 37 | $747 |
| E.r. Squibb & Sons, L.L.C. | 14 | $622 |
| Otsuka America Pharmaceutical, Inc. | 24 | $476 |
| AbbVie | 17 | $456 |
| Sunovion Pharmaceuticals Inc. | 16 | $339 |
| Vanda Pharmaceuticals Inc. | 8 | $186 |
| AstraZeneca | 1 | $125 |
| Avanir Pharmaceuticals, Inc. | 6 | $124 |
| Axsome Therapeutics, Inc. | 5 | $118 |
| Indivior Inc. | 5 | $117 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,454 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 16 | $120,151 |
| Abilify MaintenaAripiprazole | 45 | $111,242 |
| AristadaAripiprazole Lauroxil | 42 | $104,712 |
| AuvelityDextromethorphan Hbr/Bupropion | 124 | $94,603 |
| IngrezzaValbenazine Tosylate | 12 | $91,146 |
| Invega SustennaPaliperidone Palmitate | 39 | $89,815 |
| Abilify AsimtufiiAripiprazole | 16 | $81,818 |
| AustedoDeutetrabenazine | 16 | $47,968 |
| Lurasidone Hcl | 110 | $44,322 |
| UzedyRisperidone | 13 | $37,775 |
| RexultiBrexpiprazole | 13 | $17,904 |
| TrintellixVortioxetine Hydrobromide | 39 | $17,869 |
| NamzaricMemantine Hcl/Donepezil Hcl | 32 | $17,608 |
| VivitrolNaltrexone Microspheres | 11 | $16,895 |
| LunestaEszopiclone | 11 | $8,866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii, Rexulti | $476 | $210,96474 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo, Uzedy | $2,336 | $205,89545 claims |
| Alkermes, Inc.Aristada, Vivitrol | $966 | $121,60753 claims |
| Axsome Therapeutics, Inc.Auvelity | $118 | $94,603124 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $900 | $91,14612 claims |
| Johnson & JohnsonInvega Sustenna | $747 | $89,81539 claims |
| AbbVieNamzaric | $456 | $17,60832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Bronx
- George KruseBronx$1.2M
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.